DE60239394D1 - Onkolytische virustherapie - Google Patents
Onkolytische virustherapieInfo
- Publication number
- DE60239394D1 DE60239394D1 DE60239394T DE60239394T DE60239394D1 DE 60239394 D1 DE60239394 D1 DE 60239394D1 DE 60239394 T DE60239394 T DE 60239394T DE 60239394 T DE60239394 T DE 60239394T DE 60239394 D1 DE60239394 D1 DE 60239394D1
- Authority
- DE
- Germany
- Prior art keywords
- oncolytic virus
- pharmaceutical composition
- virus therapy
- subject
- human leukocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000309459 oncolytic virus Species 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 210000000265 leukocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29005101P | 2001-05-11 | 2001-05-11 | |
PCT/US2002/014642 WO2002091997A2 (en) | 2001-05-11 | 2002-05-09 | Oncolytic virus therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60239394D1 true DE60239394D1 (de) | 2011-04-21 |
Family
ID=23114328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60239394T Expired - Lifetime DE60239394D1 (de) | 2001-05-11 | 2002-05-09 | Onkolytische virustherapie |
Country Status (13)
Country | Link |
---|---|
US (3) | US7122182B2 (de) |
EP (1) | EP1385466B1 (de) |
JP (1) | JP4916641B2 (de) |
CN (1) | CN1332712C (de) |
AT (1) | ATE500808T1 (de) |
AU (1) | AU2002256510B2 (de) |
CA (1) | CA2442648C (de) |
DE (1) | DE60239394D1 (de) |
HU (1) | HUP0400882A3 (de) |
IL (1) | IL157504A0 (de) |
MX (1) | MXPA03010278A (de) |
NZ (1) | NZ527687A (de) |
WO (1) | WO2002091997A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
HUP0302278A3 (en) * | 1999-04-15 | 2011-01-28 | Pro Virus | Treatment of neoplasms with viruses |
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
NZ527687A (en) * | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
US7615209B2 (en) * | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
US20050214266A1 (en) * | 2004-03-12 | 2005-09-29 | Oncolytics Biotech Inc. | Combination of transplantation and oncolytic virus treatment |
JP5054522B2 (ja) * | 2004-08-20 | 2012-10-24 | ヴィラリティクス リミテッド | 血液ガンを治療するための方法および組成物 |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
EP1917351A4 (de) | 2005-08-01 | 2009-12-16 | Univ Technologies Int | Abgeschwächtes reovirus |
US20070077231A1 (en) | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
WO2008009115A1 (en) * | 2006-07-18 | 2008-01-24 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
US9241998B2 (en) * | 2007-05-21 | 2016-01-26 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oncolytic RSV activity |
WO2009067808A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
WO2010020247A1 (en) | 2008-08-22 | 2010-02-25 | Reapplix Aps | Multilayered blood product |
US8481297B2 (en) * | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
WO2013052915A2 (en) | 2011-10-05 | 2013-04-11 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
DK3207130T3 (da) | 2014-10-14 | 2019-11-11 | Halozyme Inc | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme |
CA2970954C (en) | 2015-01-26 | 2023-10-31 | Ottawa Hospital Research Institute | Compositions and methods for viral sensitization |
GB201504251D0 (en) | 2015-03-13 | 2015-04-29 | Virttu Biolog Ltd And University Of Sheffield The | Oncolytic herpes simplex virus infected cells |
IL262366B1 (en) | 2016-04-15 | 2024-03-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins and CD80 variants and their uses |
KR20230051601A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
PT3518948T (pt) | 2016-10-03 | 2023-07-17 | Ottawa Hospital Res Inst | Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos |
KR20190099194A (ko) | 2016-10-20 | 2019-08-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료 |
US11920156B2 (en) | 2017-02-09 | 2024-03-05 | Indapta Therapeutics, Inc. | Engineered natural killer (NK) cells and compositions and methods thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
KR20190140923A (ko) | 2017-03-16 | 2019-12-20 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l1 변이체 면역조절 단백질 및 그의 용도 |
EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
CA3177467A1 (en) | 2018-06-04 | 2019-12-12 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
EP3876951A1 (de) | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Verbesserte systeme für zellvermittelte onkolytische virustherapie |
CN113891934A (zh) | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤(nk)细胞子集的方法以及相关组合物和方法 |
US20220372106A1 (en) | 2018-11-30 | 2022-11-24 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
JP2022524951A (ja) | 2019-02-27 | 2022-05-11 | アクティム・セラピューティクス・インコーポレイテッド | 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌 |
CN116368221A (zh) | 2020-04-22 | 2023-06-30 | 因达普塔治疗公司 | 自然杀伤(nk)细胞组合物及其生成方法 |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
PT1314431E (pt) * | 1993-04-30 | 2008-10-24 | Wellstat Biologics Corp | Composições purificadas de vírus da doença de newcastle |
US5595739A (en) * | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
BR9712988A (pt) * | 1996-10-11 | 2000-10-24 | Univ California | Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos |
WO1999018799A1 (en) | 1997-10-09 | 1999-04-22 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US6177076B1 (en) * | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
EP1061806A4 (de) * | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
HUP0302278A3 (en) * | 1999-04-15 | 2011-01-28 | Pro Virus | Treatment of neoplasms with viruses |
JP3639772B2 (ja) * | 1999-06-30 | 2005-04-20 | キヤノン株式会社 | 情報処理装置および印刷システムおよび印刷制御方法およびコンピュータが読み出し可能なプログラムを格納した記憶媒体 |
EP1218019B1 (de) | 1999-09-17 | 2006-03-08 | Wellstat Biologics Corporation | Onkolytisches vesicular stomatitis virus |
US6270147B1 (en) * | 2000-01-07 | 2001-08-07 | Daimlerchrysler Corporation | Drive arrangement for a power liftgate including clutching mechanism |
JP5208343B2 (ja) * | 2000-06-26 | 2013-06-12 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いる細胞の浄化 |
NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
-
2002
- 2002-05-09 NZ NZ527687A patent/NZ527687A/en not_active IP Right Cessation
- 2002-05-09 MX MXPA03010278A patent/MXPA03010278A/es active IP Right Grant
- 2002-05-09 HU HU0400882A patent/HUP0400882A3/hu unknown
- 2002-05-09 CA CA2442648A patent/CA2442648C/en not_active Expired - Fee Related
- 2002-05-09 JP JP2002588916A patent/JP4916641B2/ja not_active Expired - Fee Related
- 2002-05-09 AU AU2002256510A patent/AU2002256510B2/en not_active Ceased
- 2002-05-09 DE DE60239394T patent/DE60239394D1/de not_active Expired - Lifetime
- 2002-05-09 WO PCT/US2002/014642 patent/WO2002091997A2/en active IP Right Grant
- 2002-05-09 IL IL15750402A patent/IL157504A0/xx not_active IP Right Cessation
- 2002-05-09 EP EP02725980A patent/EP1385466B1/de not_active Expired - Lifetime
- 2002-05-09 US US10/142,405 patent/US7122182B2/en not_active Expired - Fee Related
- 2002-05-09 AT AT02725980T patent/ATE500808T1/de not_active IP Right Cessation
- 2002-05-09 CN CNB028097009A patent/CN1332712C/zh not_active Expired - Fee Related
-
2005
- 2005-05-05 US US11/122,690 patent/US7595042B2/en not_active Expired - Fee Related
-
2009
- 2009-03-26 US US12/412,035 patent/US8137663B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1385466A2 (de) | 2004-02-04 |
CA2442648A1 (en) | 2002-11-21 |
CN1514688A (zh) | 2004-07-21 |
US8137663B2 (en) | 2012-03-20 |
US7595042B2 (en) | 2009-09-29 |
US20050208024A1 (en) | 2005-09-22 |
JP4916641B2 (ja) | 2012-04-18 |
CA2442648C (en) | 2012-10-16 |
HUP0400882A3 (en) | 2011-01-28 |
ATE500808T1 (de) | 2011-03-15 |
NZ527687A (en) | 2005-10-28 |
US7122182B2 (en) | 2006-10-17 |
AU2002256510B2 (en) | 2007-08-30 |
US20090180994A1 (en) | 2009-07-16 |
CN1332712C (zh) | 2007-08-22 |
EP1385466B1 (de) | 2011-03-09 |
IL157504A0 (en) | 2004-03-28 |
WO2002091997A3 (en) | 2003-03-13 |
JP2004521938A (ja) | 2004-07-22 |
HUP0400882A2 (hu) | 2004-07-28 |
MXPA03010278A (es) | 2004-12-06 |
EP1385466A4 (de) | 2005-10-12 |
WO2002091997A2 (en) | 2002-11-21 |
US20030077819A1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE500808T1 (de) | Onkolytische virustherapie | |
NO20026044L (no) | Behandling av humant papillomavirus | |
ES2187798T3 (es) | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. | |
BR9912653A (pt) | Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal | |
DK184186A (da) | Terapeutisk praeparat til behandling af virussygdomme | |
DE60026554D1 (de) | Onkolytisches vesicular stomatitis virus | |
CY1105818T1 (el) | Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου | |
TR200001891T2 (tr) | ASPB28- İnsan ensülini ve kullanımı. | |
MY117892A (en) | Therapeutic compounds | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
AP9801286A0 (en) | Therapeutic compounds. | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
ATE185274T1 (de) | Therapeutisches mittel gegen drohenden abortus | |
ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
ATE295159T1 (de) | Bupropion zur behandlung von viralen erkrankungen | |
EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
SG165996A1 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
DK1150981T3 (da) | Terapeutisk necleosidforbindelse | |
DE69803052T2 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
TW200513258A (en) | Auxiliary agent for hepatitis C | |
SU1565027A1 (ru) | Инактиватор вируса западного нила | |
DK0788355T3 (da) | Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme | |
HRP20030701A2 (en) | Natural antibodies active against hiv virus | |
RU99122488A (ru) | Способ лечения рака эндометрия | |
UA37445A (uk) | Протизапальний засіб |